FindTrial
Sign In

Trial of PACEBOM versus CHOP in histologically aggressive non-Hodgkins lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN24219839
Enrollment
Unknown
Registered
2001-07-01
Start date
1987-11-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (non-Hodgkins) Cancer Lymphoma (non-Hodgkins)

Interventions

Patients were randomised to one of two regimens: 1. CHOP Regimen: Multi-drug chemotherapy with cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP) repeated every 28 days. A mini

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aged 16 to 69 years 2. Previously untreated histologically aggressive lymphoma with a large cell component: Diffuse large cell, Diffuse immunoblastic, Diffuse mixed cell 3. Stages II-IV 4. No contraindications to treatment protocols

Exclusion criteria

Exclusion criteria: Patients with Burkitt's and lymphoblastic lymphoma to be excluded

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026